Importance: The mortality rate for individuals on the wait list for lung transplant is 15% to 25%, and still only 20% of lungs from multiorgan donors are used for lung transplant. The lung donor pool may be increased by assessing and reconditioning high-risk extended criteria donor lungs with ex vivo lung perfusion (EVLP), with similar short-term outcomes. Objective: To assess the long-term outcomes of transplant recipients of donor lungs treated with EVLP. Design, Setting, and Participants: This retrospective cohort single-center study was conducted from August 1, 2008, to February 28, 2017, among 706 recipients of donor lungs not undergoing EVLP and 230 recipients of donor lungs undergoing EVLP. Exposure: Donor lungs undergoing EVLP. Main Outcomes and Measures: The incidence of chronic lung allograft dysfunction and allograft survival during the 10-year EVLP era were the primary outcome measures. Secondary outcomes included donor characteristics, maximum predicted percentage of forced expiratory volume in 1 second, acute cellular rejection, and de novo donor-specific antibody development. Results: This study included 706 patients (311 women and 395 men; median age, 50 years [interquartile range, 34-61 years]) in the non-EVLP group and 230 patients (85 women and 145 men; median age, 46 years [interquartile range, 32-55 years]) in the EVLP group. The EVLP group donors had a significantly lower mean (SD) Pao2:fraction of inspired oxygen ratio than the non-EVLP group donors (348 [108] vs 422 [88] mm Hg; P < .001), higher prevalence of abnormal chest radiography results (135 of 230 [58.7%] vs 349 of 706 [49.4%]; P = .02), and higher proportion of smoking history (125 of 204 [61.3%] vs 322 of 650 [49.5%]; P = .007). More recipients in the EVLP group received single-lung transplants (62 of 230 [27.0%] vs 100 of 706 [14.2%]; P < .001). There was no significant difference in time to chronic lung allograft dysfunction between the EVLP and non-EVLP group (70% vs 72% at 3 years; 56% vs 56% at 5 years; and 53% vs 36% at 9 years; log-rank P = .68) or allograft survival between the EVLP and non-EVLP groups (73% vs 72% at 3 years; 62% vs 58% at 5 years; and 50% vs 44% at 9 years; log-rank P = .97) between the 2 groups. All secondary outcomes were similar between the 2 groups. Conclusions and Relevance: Since 2008, 230 of 936 lung transplants (24.6%) in the Toronto Lung Transplant Program were performed after EVLP assessment and treatment. Use of EVLP-treated lungs led to an increase in the number of patients undergoing transplantation, with comparable long-term outcomes.
Importance: The mortality rate for individuals on the wait list for lung transplant is 15% to 25%, and still only 20% of lungs from multiorgan donors are used for lung transplant. The lung donor pool may be increased by assessing and reconditioning high-risk extended criteria donor lungs with ex vivo lung perfusion (EVLP), with similar short-term outcomes. Objective: To assess the long-term outcomes of transplant recipients of donor lungs treated with EVLP. Design, Setting, and Participants: This retrospective cohort single-center study was conducted from August 1, 2008, to February 28, 2017, among 706 recipients of donor lungs not undergoing EVLP and 230 recipients of donor lungs undergoing EVLP. Exposure: Donor lungs undergoing EVLP. Main Outcomes and Measures: The incidence of chronic lung allograft dysfunction and allograft survival during the 10-year EVLP era were the primary outcome measures. Secondary outcomes included donor characteristics, maximum predicted percentage of forced expiratory volume in 1 second, acute cellular rejection, and de novo donor-specific antibody development. Results: This study included 706 patients (311 women and 395 men; median age, 50 years [interquartile range, 34-61 years]) in the non-EVLP group and 230 patients (85 women and 145 men; median age, 46 years [interquartile range, 32-55 years]) in the EVLP group. The EVLP group donors had a significantly lower mean (SD) Pao2:fraction of inspired oxygen ratio than the non-EVLP group donors (348 [108] vs 422 [88] mm Hg; P < .001), higher prevalence of abnormal chest radiography results (135 of 230 [58.7%] vs 349 of 706 [49.4%]; P = .02), and higher proportion of smoking history (125 of 204 [61.3%] vs 322 of 650 [49.5%]; P = .007). More recipients in the EVLP group received single-lung transplants (62 of 230 [27.0%] vs 100 of 706 [14.2%]; P < .001). There was no significant difference in time to chronic lung allograft dysfunction between the EVLP and non-EVLP group (70% vs 72% at 3 years; 56% vs 56% at 5 years; and 53% vs 36% at 9 years; log-rank P = .68) or allograft survival between the EVLP and non-EVLP groups (73% vs 72% at 3 years; 62% vs 58% at 5 years; and 50% vs 44% at 9 years; log-rank P = .97) between the 2 groups. All secondary outcomes were similar between the 2 groups. Conclusions and Relevance: Since 2008, 230 of 936 lung transplants (24.6%) in the Toronto Lung Transplant Program were performed after EVLP assessment and treatment. Use of EVLP-treated lungs led to an increase in the number of patients undergoing transplantation, with comparable long-term outcomes.
Authors: Takahiro Oto; Bronwyn J Levvey; Helen Whitford; Anne P Griffiths; Tom Kotsimbos; Trevor J Williams; Gregory I Snell Journal: Ann Thorac Surg Date: 2007-01 Impact factor: 4.330
Authors: Marcelo Cypel; Jonathan C Yeung; Mingyao Liu; Masaki Anraku; Fengshi Chen; Wojtek Karolak; Masaaki Sato; Jane Laratta; Sassan Azad; Mindy Madonik; Chung-Wai Chow; Cecilia Chaparro; Michael Hutcheon; Lianne G Singer; Arthur S Slutsky; Kazuhiro Yasufuku; Marc de Perrot; Andrew F Pierre; Thomas K Waddell; Shaf Keshavjee Journal: N Engl J Med Date: 2011-04-14 Impact factor: 91.245
Authors: M Valapour; K Paulson; J M Smith; M I Hertz; M A Skeans; B M Heubner; L B Edwards; J J Snyder; A K Israni; B L Kasiske Journal: Am J Transplant Date: 2013-01 Impact factor: 8.086
Authors: Jussi M Tikkanen; Lianne G Singer; S Joseph Kim; Yanhong Li; Matthew Binnie; Cecilia Chaparro; Chung-Wai Chow; Tereza Martinu; Sassan Azad; Shaf Keshavjee; Kathryn Tinckam Journal: Am J Respir Crit Care Med Date: 2016-09-01 Impact factor: 21.405
Authors: Keith C Meyer; Ganesh Raghu; Geert M Verleden; Paul A Corris; Paul Aurora; Kevin C Wilson; Jan Brozek; Allan R Glanville Journal: Eur Respir J Date: 2014-10-30 Impact factor: 16.671
Authors: Carlos Gutierrez; R Heberto Ghezzo; Raja T Abboud; Manuel G Cosio; John R Dill; Richard R Martin; Dan S McCarthy; John L C Morse; Noe Zamel Journal: Can Respir J Date: 2004-09 Impact factor: 2.409
Authors: Marcelo Cypel; Jonathan C Yeung; Shin Hirayama; Matthew Rubacha; Stefan Fischer; Masaki Anraku; Masaaki Sato; Stephen Harwood; Andrew Pierre; Thomas K Waddell; Marc de Perrot; Mingyao Liu; Shaf Keshavjee Journal: J Heart Lung Transplant Date: 2008-12 Impact factor: 10.247
Authors: Samantha E Halpern; Samuel J Kesseli; Sandra Au; Madison K Krischak; Danae G Olaso; Haley Smith; Greg Tipton; Ian R Jamieson; Andrew S Barbas; John C Haney; Jacob A Klapper; Matthew G Hartwig Journal: Am J Transplant Date: 2021-09-02 Impact factor: 8.086
Authors: Oliver K Jawitz; Vignesh Raman; David Becerra; Julie Doberne; Ashley Y Choi; Samantha E Halpern; Jacob A Klapper; Matthew G Hartwig Journal: Ann Surg Date: 2020-07-24 Impact factor: 13.787
Authors: Samantha E Halpern; Sandra Au; Samuel J Kesseli; Madison K Krischak; Danae G Olaso; Brandi A Bottiger; John C Haney; Jacob A Klapper; Matthew G Hartwig Journal: J Heart Lung Transplant Date: 2021-06-23 Impact factor: 10.247